Progyny, Inc. (NASDAQ:PGNY) Shares Bought by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE raised its stake in Progyny, Inc. (NASDAQ:PGNY) by 27.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,319 shares of the company’s stock after acquiring an additional 32,344 shares during the period. Congress Wealth Management LLC DE’s holdings in Progyny were worth $5,735,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of PGNY. Acadian Asset Management LLC acquired a new position in Progyny in the third quarter valued at $53,000. Federated Hermes Inc. boosted its stake in Progyny by 16.5% in the third quarter. Federated Hermes Inc. now owns 26,648 shares of the company’s stock valued at $907,000 after acquiring an additional 3,771 shares in the last quarter. Northern Trust Corp boosted its stake in Progyny by 1.3% in the third quarter. Northern Trust Corp now owns 1,166,806 shares of the company’s stock valued at $39,695,000 after acquiring an additional 15,208 shares in the last quarter. PEAK6 Investments LLC acquired a new position in Progyny in the third quarter valued at $288,000. Finally, Qube Research & Technologies Ltd boosted its stake in Progyny by 27.6% in the third quarter. Qube Research & Technologies Ltd now owns 135,518 shares of the company’s stock valued at $4,610,000 after acquiring an additional 29,273 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Stock Performance

NASDAQ:PGNY traded down $0.23 during mid-day trading on Monday, reaching $28.38. The stock had a trading volume of 1,243,484 shares, compared to its average volume of 971,181. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of 46.52, a PEG ratio of 1.85 and a beta of 1.46. Progyny, Inc. has a twelve month low of $23.90 and a twelve month high of $44.95. The business has a 50 day simple moving average of $28.52 and a 200 day simple moving average of $34.14.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Progyny had a net margin of 5.53% and a return on equity of 11.61%. The firm had revenue of $278.08 million during the quarter, compared to the consensus estimate of $289.41 million. During the same quarter last year, the firm earned $0.18 earnings per share. The firm’s revenue was up 7.6% compared to the same quarter last year. As a group, sell-side analysts expect that Progyny, Inc. will post 0.73 earnings per share for the current year.

Insider Buying and Selling at Progyny

In other Progyny news, Director Cheryl Scott sold 1,462 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $28.39, for a total value of $41,506.18. Following the completion of the transaction, the director now directly owns 10,098 shares of the company’s stock, valued at $286,682.22. The sale was disclosed in a filing with the SEC, which is available at this link. In other Progyny news, President Michael E. Sturmer sold 4,515 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total value of $144,254.25. Following the completion of the transaction, the president now directly owns 380,038 shares of the company’s stock, valued at $12,142,214.10. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Cheryl Scott sold 1,462 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $28.39, for a total transaction of $41,506.18. Following the transaction, the director now directly owns 10,098 shares of the company’s stock, valued at $286,682.22. The disclosure for this sale can be found here. 12.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PGNY shares. KeyCorp downgraded shares of Progyny from an “overweight” rating to a “sector weight” rating in a research note on Friday, May 10th. Barclays decreased their target price on shares of Progyny from $48.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, May 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $48.00 target price on shares of Progyny in a research note on Thursday, May 16th. BTIG Research decreased their target price on shares of Progyny from $50.00 to $41.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Finally, Truist Financial decreased their target price on shares of Progyny from $46.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 17th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and a consensus price target of $43.11.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.